Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email

Fascinating article from the Italian NET scientific community.  This article is more than just what the title says, it provides overviews on many facets of NETs including markers, scans and PRRT itself. It covers how to select patients for PRRT in the first place, i.e. who is most likely to get a good response to this treatment and then look at how to track and assess that response.

The important thing I gathered from reading is that none of this is a precise science, there are too many variables.  And while this article focusses on the clinical factors, there can of course be non-clinical factors in play in different countries and healthcare systems.  For example, for years in my own country (UK), access to PRRT was quite limited before formal approval and was rationed for compassionate use.  Only those with the greatest need would get access. In a similar vein, countries may have short or limited supplies, even since being formally authorised, and may therefore operate a similar rationing programme.  Even in advanced economies with advanced healthcare, there can be limits based whether a particular person has a need and in the case of insurance-based approvals, whether it can be funded within the guidelines.

For those with an interest in PRRT this is a great read but long and technical in places.   Click here to read.

This guidance document co-authored by the North American Neuroendocrine Tumors Society (NANETS) and The Society of Nuclear Medicine and Molecular Imaging (SNMMI) takes a more practical look at the selection of patients. Click here to read.

Reference:

Liberini, V.; Huellner, M.W.; Grimaldi, S.; Finessi, M.; Thuillier, P.; Muni, A.; Pellerito, R.E.; Papotti, M.G.; Piovesan, A.; Arvat, E.; Deandreis, D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics 202010, 1083.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

 

Thanks for reading.

Ronny


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters –  Click Here 

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my Podcast Interview (click and press play)

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

wego-blog-2018-winner

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 17,106 other subscribers.

2 thoughts on “Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future

  • Michael Deutsch

    Thank you for posting the important paper “The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.” However, pages 2 through 13 appear to be missing. Any thoughts on where they might be available?

    Thanks and best regards,

I love comments - feel free!

%d bloggers like this: